Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

Publications

Aslan NA, Hıncal HO, Elver Ö, Erol V, Güler N

Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2023;29(2):511-516

Liu QS, Ass'ad NA, Arana Yi C

Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.

Clinical case reports. 2021;9(5):e03164

Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

American journal of hematology. 2014;89(7):732-42

Shen AQ, Wilson NM, Gleason SL, Khoury HJ

Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.

Therapeutic advances in hematology. 2014;5(1):13-7

Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

Blood. 2011;118(17):4567-76